Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

Exclusion Criteria

• •1. Bleeding disorder(s) other than hemophilia A or B.
• •2. Personal laboratory evidence of having developed inhibitors to FVIII or FIX protein at any time (≥0.6 Bethesda Units \[BU\] on any single test).
• •3. Currently receiving systemic immunosuppressive therapy, cytotoxic chemotherapy, immunoglobulin therapy, or monoclonal antibody therapy.
• •4. Received systemic antiviral and/or interferon therapy within 30 days of blood draw, with the exception of treatment for human immunodeficiency virus (HIV).
• •5. Currently receiving ribavirin and/or interferon based therapy for active hepatitis C virus (HCV).
• •6. Received immunoglobulin therapy or plasma infusion within 120 days of the blood draw.
• •7. Has a known immune deficiency other than HIV.
• •8. Has lymphocyte or plasma cell malignancies.
• •9. Participant is a family member or employee of the investigator.